FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
Researchers used a novel PET tracer to visualize how ketamine alters AMPA receptor distribution in the brains of patients with treatment-resistant depression. Receptor density increased in cortical ...
Construction and development specialist Seddon has completed enabling work to support the installation of UK-first Siemens Healthineers cancer imaging technology at a site on the Wirral.
Claritas NucMed Technologies Ltd (Claritas), a healthcare technology company specializing in state-of-the-art image ...
Major depressive disorder (MDD) is a major global health problem and one of the leading causes of disability. About 30% of people diagnosed with ...
MedVersa, a generalist multimodal AI model trained on tens of millions of medical imaging instances to perform diverse radiology tasks within a single framework. The model matched or exceeded ...
A new brain-imaging study has revealed how ketamine produces its fast antidepressant effects in people with treatment-resistant depression. Researchers tracked changes in a critical brain receptor ...
Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond ...
RadNet's management reported record Q4 2025 revenue, while underlying organic growth of the base imaging business is still healthy. See why RDNT stock is a strong buy.
The Life Vincent Pallotti Hospital in Cape Town has recently improved its cancer diagnostics by installing a digital PET-CT (positron emission tomography-computed tomography) scanner. This scanner, a ...
The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate cancer, according to an industry press release. As Healio previously reported, ...
New formulation of its widely-used U.S. market-leading PSMA PET imaging agentcombines thediagnostic performance of PYLARIFY® (piflufolastat F 18) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results